Methods of reducing mammographic breast density and/or breast cancer risk

作者: Stephen Nigel Birrell

DOI:

关键词:

摘要: The present disclosure is directed to generally methods for treating mammographic breast density and/or stiffness in a patient need thereof, such as premenopausal or perimenopausal patient, comprising the administration of an effective amount androgenic agent and aromatase inhibitor. These may also be useful post-menopausal woman.

参考文章(144)
Gabriella Piscitelli, Dinesh Purandare, Giorgio Massimini, Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents ,(2001)
Jürg Andreas Gasser, Ajay S. Bhatnagar, Jonathan Green, Dean Brent Evans, Combination of an aromatase inhibitor with a bisphosphonate ,(2003)
Johanna Olga Pauline Wanders, Marije Fokje Bakker, Wouter Bernard Veldhuis, Petra Huberdina Maria Peeters, Carla Henrica van Gils, None, The effect of weight change on changes in breast density measures over menopause in a breast cancer screening cohort Breast Cancer Research. ,vol. 17, pp. 74- 74 ,(2015) , 10.1186/S13058-015-0583-2
Pol Boudes, Matthew L. Sherman, Simon N. Jenkins, Barry S. Komm, Philip Frost, Treatment of aromatase inhibitor therapy-related osteoporosis ,(2005)
HATEM ABU HASHIM, MOHAMED EL RAKHAWY, IBRAHIM ABD ELAAL, Randomized comparison of superovulation with letrozole vs. clomiphene citrate in an IUI program for women with recently surgically treated minimal to mild endometriosis Acta Obstetricia et Gynecologica Scandinavica. ,vol. 91, pp. 338- 345 ,(2012) , 10.1111/J.1600-0412.2011.01346.X